First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion. (English)
In: Chinese Journal of Lung Cancer, Jg. 27 (2024-03-01), Heft 3, S. 241-244
Online
academicJournal
Zugriff:
With the continuous innovation of genomics, proteomics and molecular biological detection technology, the treatment of non-small cell lung cancer (NSCLC) has changed from traditional chemotherapy to immunotherapy and targeted therapy. Among them, molecular tumor markers targeting tyrosine kinase pathways play more important roles in clinical practice. For advanced NSCLC patients with positive epidermal growth factor receptor (EGFR) mutations, there are many first-line drugs on the market and they could bring significant efficacy, thus completely subverting the treatment pattern of advanced NSCLC. Common mutations of EGFR in Chinese patients are located on exons 19, 20 and 21, of which exons 19 and 21 mutations are the more common types. Besides, there is also a subtype of EGFR mutations, known as EGFR 20 exon insertion (EGFR 20ins) mutation. The authors summarized the treatment of a lung adenocarcinoma patient with EGFR 20ins mutation accepting Furmonertinib mesylate, in order to provide effective references for clinical diagnosis and treatment. [ABSTRACT FROM AUTHOR]
Copyright of Chinese Journal of Lung Cancer is the property of Chinese Journal of Lung Cancer and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
First-line Treatment with Furmonertinib Mesylate in Lung Adenocarcinoma Patient with EGFR Exon 20 Insertion Mutantion. (English)
|
---|---|
Autor/in / Beteiligte Person: | Zhengguo, LI ; Ting, WEI ; Duo, ZENG ; Li, ZHAO ; Jianting, ZHANG ; Laixiu, CHEN |
Link: | |
Zeitschrift: | Chinese Journal of Lung Cancer, Jg. 27 (2024-03-01), Heft 3, S. 241-244 |
Veröffentlichung: | 2024 |
Medientyp: | academicJournal |
ISSN: | 1009-3419 (print) |
DOI: | 10.3779/j.issn.1009-3419.2024.102.11 |
Schlagwort: |
|
Sonstiges: |
|